In short
This article explores the ongoing clinical trials of EO2463, a groundbreaking cancer vaccine therapy being tested for patients with indolent Non-Hodgkin's Lymphoma. The study aims to evaluate the safety, efficacy, and potential combinations of EO2463 with other treatments like lenalidomide and rituximab. This innovative approach could offer new hope for patients with Follicular Lymphoma and Marginal Zone Lymphoma.
At a glance
- Study Drug
- EO2463 (novel microbial-derived peptide therapeutic vaccine)
- Target Condition
- Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
- Study Phase
- Phase 1/2
- Primary Objectives
- Determine recommended Phase 2 dose, assess safety, evaluate objective response rate
- Treatment Combinations
- EO2463 alone, with lenalidomide, with rituximab, or with both lenalidomide and rituximab
- Key Eligibility Criteria
- Age ≥18, HLA-A2 positive, specific lymphoma diagnoses
- Study Duration
- 9-12 months active treatment, 24 months short-term follow-up, 5 years long-term follow-up
- Key Assessments
- Safety, efficacy, immunogenicity, changes in B and T cell levels
What is EO2463?
EO2463 is a new type of cancer treatment called a microbial-derived peptide therapeutic vaccine. It is currently being studied for the treatment of certain types of indolent Non-Hodgkin's Lymphoma (NHL), specifically Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL).
This innovative therapy is composed of five key components: UCP2, OMP72, OMP64, OMP65, and OMP66. These are all proteins that have been carefully selected to target specific aspects of lymphoma cells.
Target Conditions
EO2463 is being developed to treat two specific types of indolent (slow-growing) Non-Hodgkin's Lymphoma:
- Follicular Lymphoma (FL): A type of lymphoma that develops from B-lymphocytes and typically grows slowly.
- Marginal Zone Lymphoma (MZL): Another slow-growing lymphoma that can occur in several forms, including:
- Extranodal MZL (EMZL, also known as MALT lymphoma)
- Splenic MZL (SMZL)
- Nodal MZL (NMZL)
These lymphomas are considered "indolent" because they tend to grow and spread slowly, often not causing symptoms for a long time.
How EO2463 Works
EO2463 is designed to stimulate the patient's immune system to recognize and attack lymphoma cells. It works by:
- Introducing specific peptides (small protein fragments) that resemble parts of lymphoma cells
- Training the immune system, particularly T cells, to recognize these peptides
- Encouraging the immune system to attack cells displaying these peptides, which should be the lymphoma cells
The vaccine targets specific B-cell antigens, including CD20, CD22, CD37, and BAFF-receptor, which are commonly found on lymphoma cells.
Clinical Trial Details
EO2463 is currently being studied in a Phase 1/2 clinical trial. This trial is designed to:
- Determine the safe and effective dose of EO2463 (Phase 1)
- Evaluate how well EO2463 works in treating indolent NHL (Phase 2)
- Study EO2463 alone and in combination with other drugs (lenalidomide and rituximab)
The trial includes several patient groups (cohorts) to test different treatment approaches:
- EO2463 alone in previously treated patients
- EO2463 alone in untreated patients
- EO2463 followed by rituximab in untreated patients
- EO2463 with lenalidomide and rituximab in previously treated patients
Potential Benefits
The researchers hope that EO2463 will provide several benefits for patients with indolent NHL:
- Improved response rates to treatment
- Longer-lasting remissions
- Potentially fewer side effects compared to traditional chemotherapy
- A new option for patients who have not responded well to other treatments
The trial will measure these benefits by looking at factors such as the objective response rate (ORR), duration of response (DOR), time to next anti-lymphoma therapy (TTT), progression-free survival (PFS), and overall survival (OS).
Safety Considerations
As with any new treatment, safety is a primary concern. The trial will closely monitor patients for:
- Side effects (adverse events)
- Changes in blood cell counts and immune system function
- Any unexpected reactions to the vaccine
Patients will be followed for up to 5 years after treatment to assess long-term safety.
Eligibility Criteria
To participate in this trial, patients must meet certain criteria, including:
- Being 18 years or older
- Having confirmed FL or MZL
- Being HLA-A2 positive (a specific genetic marker)
- Having measurable disease
- Meeting specific health requirements
There are also several factors that may exclude a patient from participating, such as certain prior treatments, other medical conditions, or pregnancy.
If you're interested in this trial, it's important to discuss your eligibility with your healthcare provider, who can provide more detailed information about whether this study might be appropriate for you.